Jeyyam Global Foods Limited IPO And Its GMP...
17 Apr, 2025
Onyx Biotec Limited IPO, GMP, Details, Price, And Review
Onyx Biotec Limited, established in May 2005, is a pharmaceutical company that specializes in the production of sterile water for injections. In addition to manufacturing sterile water, the company also offers contract manufacturing services for a variety of pharmaceutical products, including dry powder injections and dry syrups.
These products are distributed both in the Indian market and internationally. Onyx Biotec's clients include prominent pharmaceutical companies such as Hetero Healthcare, Mankind Pharma, Sun Pharmaceutical Industries, Aristo Pharmaceuticals, Macleods Pharmaceuticals, Mapra Laboratories, Axa Parenterals, FDC Limited, Zuventus Healthcare, Akums Drugs, and Reliance Life Sciences, among others.
Onyx Biotec IPO Overview:
• Issue Size: â¹29.34 crores (entirely fresh issue)
•Total Shares: 48.1 lakh equity shares
• Price Band: â¹58 to â¹61 per share
•Minimum Lot Size: 2,000 shares (can be applied for in multiples of 2,000)
•IPO Opening Date: November 13, 2024
•IPO Closing Date: November 18, 2024
•Lead Manager: Horizon Management Private Limited
•Registrar: Mas Services Limited
WHAT IS GMP?
GMP (Grey Market Premium) is the difference between the IPO price and the grey market price. It is the premium amount paid for the traded IPO shares. It plays an important role in IPOs as it reflects how the IPO would react on the listing day.
A grey market is a place where shares/stocks are traded before being listed officially on the stock exchange.
Onyx Biotec Limited IPO, GMP, Details, Price, And Review
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| 2024-11-11 | 61 | 5 (8.20%) | 2024-11-11 |
**The GMP prices displayed here are solely for informational purposes related to the grey market news. India IPO does not engage in or facilitate grey market trading, nor are these rates (sub2) indicative of any trading activity. We also do not recommend or endorse participation in the grey market.**
Onyx Biotec Limited IPO, GMP, Details, Price, And Review Details
| Detail | Description |
|---|---|
| IPO Date | November 13, 2024 to November 18, 2024 |
| Listing Date | - |
| Face Value | ₹10 per share |
| Price Band | ₹58 to ₹61 per share |
| Lot Size | 2000 Shares |
| Total Issue Size | 4,810,000 shares (aggregating up to ₹29.34 Cr) |
| Fresh Issue | 4,810,000 shares (aggregating up to ₹29.34 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Shareholding pre issue | 13,322,200 |
| Shareholding post issue | 18,132,200 |
| Market Maker portion | 244,000 shares |
Onyx Biotec Limited IPO, GMP, Details, Price, And Review Timeline
| Detail | Description |
|---|---|
| IPO Open Date | Wednesday, November 13, 2024 |
| IPO Close Date | Monday, November 18, 2024 |
| Basis of Allotment | Tuesday, November 19, 2024 |
| Initiation of Refunds | Wednesday, November 20, 2024 |
| Credit of Shares to Demat | Wednesday, November 20, 2024 |
| Listing Date | Thursday, November 21, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on November 18, 2024 |
Onyx Biotec Limited IPO, GMP, Details, Price, And Review Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| - | - | - | - |
Onyx Biotec Limited IPO, GMP, Details, Price, And Review Promoter Holding
| Share Holding Pre Issue | Share Holding Post Issue |
|---|---|
| 88.60% | - |
Competitive Strength:
- -
Onyx Biotec Limited IPO, GMP, Details, Price, And Review Financial Information
| Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Total Borrowing | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 May 2024 | 7,476.57 | 1,054.11 | 130.77 | 2,618.64 | 3,156.14 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2024 | 7,413.58 | 5,387.43 | 303.16 | 2,487.87 | 3,078.04 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2023 | 5,872.36 | 3,961.65 | 184.46 | 1,820.16 | 2,922.83 | |||||||||||||||||||||||||||||||||||
| 31 Mar 2022 | 3,683.84 | 4,498.09 | 335.29 | 1,637.59 | 1,224.39 | |||||||||||||||||||||||||||||||||||
| Amount in ₹ Crore | ||||||||||||||||||||||||||||||||||||||||
Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 10.58% |
| ROCE | 12.19% |
| Debt/Equity | 1.24 |
| RoNW | 12.19% |
| Price/Earning P/E Ratio | N/A |
| PAT Margin (%) | 5.64% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 2.28 | 4.33 |
| P/E (x) | 26.81 | 14.1 |
Objectives of Onyx Biotec IPO
- The Company proposes to utilize the Net Proceeds from the Issue towards the following objectives:
- Upgradation of existing manufacturing Unit I to manufacture large volume parenterals for intravenous use.
- Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections.
- Prepayment or repayment of all or a portion of certain loans availed by the Company.
- General Corporate Purposes.
